ROCO
6236
Market cap22mUSD
Oct 02, Last price
16.90TWD
Name
Neith Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Neith Corporation operates in diverse sectors, encompassing biotechnology, medical aesthetics, and preventive health solutions. The company provides a variety of nutritional supplements, including L-One, a liquid formula designed to support ocular well-being, and EPlus, a multi-enzyme blend. Additional nutritional offerings are marketed under the King One brand. Beyond supplements, Neith also offers genetic testing services. Its product portfolio extends to a wide array of wellness and energy-enhancing items, such as versatile mattresses (energy and dual-purpose), energy-infused masks, silicon gel necklaces, waistbands, heated energy stones, and massage tools. The company further supplies water purification systems and specialized Ganbanyoku energy stone spa beds. In the beauty segment, Neith presents a line of skincare products focused on cell regeneration and rejuvenation. Other offerings include energy-focused household items, as well as microcontrollers and their associated peripheral devices. Established in 1997, Neith Corporation was initially known as Come True Biomedical Inc. The company's headquarters are situated in Taichung, Taiwan.
Key people
Yifang Wu
Head of Finance & Accounting, Corporate Governance Officer · since 2025
Qianping Che
Director · since 2025
Xingyou Chen
Director · since 2025
Jianhong Lin
Director · since 2025
Boyu Lin
Director · since 2021
Yuefeng Lin
General Manager, Director · since 2025
Chengye Wu
Director · since 2019
Junjia Zhang
Director · since 2019
Howard Chen
Independent Director · since 2013
Xuwei Fang
Independent Director · since 2013
Chengyi Liu
Independent Director · since 2025
Hongpeng Rao
Independent Director · since 2022
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||